EP1755596A4 - Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes - Google Patents

Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes

Info

Publication number: EP1755596A4
Authority: EP; European Patent Office
Prior art keywords: preparation; new forms; atazanavir bisulfate; atazanavir; bisulfate
Prior art date: 2004-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP05744537A

Other languages

German (de)

English (en)

Other versions

EP1755596B1 (fr

EP1755596A2 (fr

EP1755596B9 (fr

Inventor

Soojin Kim

Bruce T Lotz

Mary F Malley

Jack Z Gougoutas

Martha Davidovich

Sushil K Srivastava

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Holdings Ireland ULC

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-04

Filing date

2005-05-03

Publication date

2010-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35310244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1755596(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-03 Priority to EP15180557.9A priority Critical patent/EP2980074A1/fr

2005-05-03 Priority to PL05744537T priority patent/PL1755596T3/pl

2005-05-03 Priority to HRP20150962TT priority patent/HRP20150962T2/hr

2005-05-03 Priority to EP20130175944 priority patent/EP2669273A1/fr

2005-05-03 Priority to SI200532001T priority patent/SI1755596T1/sl

2005-05-03 Priority to MEP-2015-653A priority patent/ME02261B/me

2005-05-03 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-02-28 Publication of EP1755596A2 publication Critical patent/EP1755596A2/fr

2010-12-29 Publication of EP1755596A4 publication Critical patent/EP1755596A4/fr

2015-08-12 Publication of EP1755596B1 publication Critical patent/EP1755596B1/fr

2015-11-10 Priority to CY20151101005T priority patent/CY1116919T1/el

2016-02-10 Publication of EP1755596B9 publication Critical patent/EP1755596B9/fr

2016-02-10 Application granted granted Critical

2025-05-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/127—Preparation from compounds containing pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)

EP05744537.1A 2004-05-04 2005-05-03 Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes Expired - Lifetime EP1755596B9 (fr)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
EP15180557.9A EP2980074A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
PL05744537T PL1755596T3 (pl)	2004-05-04	2005-05-03	Proces do wytwarzania wodorosiarczanu atazanawiru oraz nowe formy
HRP20150962TT HRP20150962T2 (hr)	2004-05-04	2005-05-03	Postupak za pripremu atazanavir bisulfata i novih oblika
EP20130175944 EP2669273A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
SI200532001T SI1755596T1 (sl)	2004-05-04	2005-05-03	Postopek za pripravo atazanavir bisulfata in novih oblik
MEP-2015-653A ME02261B (me)	2004-05-04	2005-05-03	Postupak za pripremu atazanavir bisulfata i novih oblika
CY20151101005T CY1116919T1 (el)	2004-05-04	2015-11-10	Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US56804304P	2004-05-04	2004-05-04
US60753304P	2004-09-07	2004-09-07
US11/119,558 US7829720B2 (en)	2004-05-04	2005-05-02	Process for preparing atazanavir bisulfate and novel forms
PCT/US2005/015333 WO2005108349A2 (fr)	2004-05-04	2005-05-03	Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes

Related Child Applications (3)

Application Number	Title	Priority Date	Filing Date
EP20130175944 Division-Into EP2669273A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
EP15180557.9A Division EP2980074A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
EP15180557.9A Division-Into EP2980074A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes

Publications (4)

Publication Number	Publication Date
EP1755596A2 EP1755596A2 (fr)	2007-02-28
EP1755596A4 true EP1755596A4 (fr)	2010-12-29
EP1755596B1 EP1755596B1 (fr)	2015-08-12
EP1755596B9 EP1755596B9 (fr)	2016-02-10

Family

ID=35310244

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP15180557.9A Ceased EP2980074A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
EP20130175944 Withdrawn EP2669273A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
EP05744537.1A Expired - Lifetime EP1755596B9 (fr)	2004-05-04	2005-05-03	Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP15180557.9A Ceased EP2980074A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes
EP20130175944 Withdrawn EP2669273A1 (fr)	2004-05-04	2005-05-03	Procédé de préparation de bisulfate d'atanazavir et nouvelles formes

Country Status (20)

Country	Link
US (3)	US7829720B2 (fr)
EP (3)	EP2980074A1 (fr)
JP (1)	JP5086069B2 (fr)
KR (1)	KR101153606B1 (fr)
AU (2)	AU2005240622B2 (fr)
BR (1)	BRPI0509595B8 (fr)
CA (2)	CA2777216A1 (fr)
CY (1)	CY1116919T1 (fr)
DK (1)	DK1755596T5 (fr)
ES (1)	ES2552219T3 (fr)
HR (1)	HRP20150962T2 (fr)
HU (1)	HUE026242T2 (fr)
IL (1)	IL178965A (fr)
MX (1)	MXPA06012612A (fr)
NO (1)	NO341013B1 (fr)
PL (1)	PL1755596T3 (fr)
PT (1)	PT1755596E (fr)
RS (1)	RS54284B1 (fr)
SI (1)	SI1755596T1 (fr)
WO (1)	WO2005108349A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200534879A (en) *	2004-03-25	2005-11-01	Bristol Myers Squibb Co	Coated tablet formulation and method
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) *	2004-05-04	2005-11-17	Soojin Kim	Process employing controlled crystallization in forming crystals of a pharmaceutical
TWI415635B (zh)	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
US7642049B2 (en) *	2006-06-30	2010-01-05	Bristol-Myers Squibb Company	Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
PL2003120T3 (pl) *	2007-06-12	2010-04-30	Concert Pharmaceuticals Inc	Pochodne azapeptydu jako inhibitory proteazy HIV
SI2170292T1 (sl) *	2007-06-22	2014-05-30	Bristol-Myers Squibb Holdings Ireland	Tabletirani sestavki, ki vsebujejo atazanavir
ATE499927T1 (de) *	2007-06-22	2011-03-15	Bristol Myers Squibb Co	Tablettierte atazanavirhaltige zusammensetzungen
WO2009002829A2 (fr) *	2007-06-22	2008-12-31	Bristol-Myers Squibb Company	Compositions en comprimés contenant de l'atazanavir
ES2359770T3 (es) *	2007-06-22	2011-05-26	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
US8552036B2 (en)	2009-01-12	2013-10-08	Hetero Research Foundation	Polymorph of atazanavir sulfate
WO2011027324A1 (fr)	2009-09-03	2011-03-10	Ranbaxy Laboratories Limited	Formes polymorphes du sulfate d'atazanavir
CA2777937C (fr)	2009-10-26	2017-08-29	Merck Sharp & Dohme Corp.	Compositions pharmaceutiques solides contenant un inhibiteur d'integrase
US20130203759A1 (en)	2010-04-09	2013-08-08	Faranak Nikfar	ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EA201390464A1 (ru)	2010-09-28	2013-08-30	Рациофарм Гмбх	Способ сухой обработки атазанавира
WO2013014633A1 (fr)	2011-07-27	2013-01-31	Ranbaxy Laboratories Limited	Procédé de préparation d'atazanavir ou de son sel bisulfate
US8461347B2 (en)	2011-08-05	2013-06-11	Scinopharm Taiwan, Ltd.	Process for preparing form A of atazanavir sulfate
WO2014030173A2 (fr) *	2012-08-24	2014-02-27	Laurus Labs Private Limited	Procédé amélioré pour préparer de l'atazanavir disulfate
WO2014036690A1 (fr) *	2012-09-04	2014-03-13	上海迪赛诺化学制药有限公司	Procédé de préparation d'un cristal de type a de bisulfate d'atazanavir
EP2956439B1 (fr)	2013-02-12	2019-01-09	Cipla Limited	Procédé de production de sulfate d'atazanavir
CN114763336A (zh) *	2021-01-14	2022-07-19	威智医药有限公司	一种硫酸阿扎那韦晶型的生产方法
CN115215792A (zh) *	2022-06-27	2022-10-21	江西富祥药业股份有限公司	一种制备阿扎那韦或其硫酸盐的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US658435A (en) *	1900-03-22	1900-09-25	William T Ginn	Coal-digger.
US4022776A (en)	1974-01-31	1977-05-10	Otsuka Pharmaceutical Company Limited	5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
US3980637A (en)	1975-03-17	1976-09-14	Bristol-Myers Company	Production of amoxicillin
DE3403329A1 (de)	1984-02-01	1985-08-01	Horst Dr. 4019 Monheim Zerbe	Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja)	1984-10-04	1986-05-01	日本碍子株式会社	セラミックス複合構造体及びその製造法
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en)	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
CA2068402C (fr)	1991-06-14	1998-09-22	Michael R. Hoy	Enrobage pour masquer le gout pouvant etre utilise dans des comprimes pharmaceutiques croquables
US5428048A (en)	1993-11-08	1995-06-27	American Home Products Corporation	Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en)	1994-04-14	1994-06-08	Smithkline Beecham Plc	Pharmaceutical formulation
TW483763B (en)	1994-09-02	2002-04-21	Astra Ab	Pharmaceutical composition comprising of ramipril and dihydropyridine compound
KR100486051B1 (ko) *	1996-04-22	2005-09-09	노파르티스 아게	항바이러스활성헤테로시클릭아자헥산유도체
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
GB9715896D0 (en)	1997-07-28	1997-10-01	Sca Packaging Ltd	Containers
US6087383A (en) *	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
FR2779726B1 (fr)	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
AU765128B2 (en)	1999-03-22	2003-09-11	Bristol-Myers Squibb Company	Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU1304601A (en)	1999-11-11	2001-06-06	Kyorin Pharmaceutical Co. Ltd.	Solid preparations for oral use
ES2275654T5 (es)	2000-01-21	2012-06-07	Novartis Ag	Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US6254888B1 (en)	2000-01-28	2001-07-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Method for coating pharmaceutical dosage forms
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
YU34501A (sh)	2000-05-26	2003-10-31	Pfizer Products Inc.	Postupak reaktivne kristalizacije radi povećanja veličine čestica
IL145106A0 (en)	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en)	2000-09-14	2003-12-30	Bristol-Myers Squibb Company	Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
AU2002248792B2 (en)	2001-04-18	2006-09-21	Nostrum Pharmaceuticals Inc.	A novel coating for a sustained release pharmaceutical composition
WO2003059330A1 (fr)	2002-01-15	2003-07-24	Ranbaxy Laboratories Limited	Compositions pharmaceutiques stables comprenant un(des) inhibiteur(s) de l'enzyme de conversion
KR100456833B1 (ko)	2002-08-01	2004-11-10	주식회사 대웅	아목시실린 및 클라불라네이트를 함유하는 유핵정
TW200534879A (en)	2004-03-25	2005-11-01	Bristol Myers Squibb Co	Coated tablet formulation and method
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en)	2004-05-04	2005-11-17	Soojin Kim	Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en)	2004-05-19	2005-12-29	Andrew Rusowicz	Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh)	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法

2005
- 2005-05-02 US US11/119,558 patent/US7829720B2/en active Active
- 2005-05-03 JP JP2007511502A patent/JP5086069B2/ja not_active Expired - Lifetime
- 2005-05-03 CA CA2777216A patent/CA2777216A1/fr not_active Abandoned
- 2005-05-03 AU AU2005240622A patent/AU2005240622B2/en not_active Expired
- 2005-05-03 DK DK05744537.1T patent/DK1755596T5/en active
- 2005-05-03 PT PT57445371T patent/PT1755596E/pt unknown
- 2005-05-03 HR HRP20150962TT patent/HRP20150962T2/hr unknown
- 2005-05-03 KR KR1020067025370A patent/KR101153606B1/ko not_active Expired - Lifetime
- 2005-05-03 ES ES05744537.1T patent/ES2552219T3/es not_active Expired - Lifetime
- 2005-05-03 CA CA2565629A patent/CA2565629C/fr not_active Expired - Lifetime
- 2005-05-03 BR BRPI0509595A patent/BRPI0509595B8/pt active IP Right Grant
- 2005-05-03 RS RS20150653A patent/RS54284B1/sr unknown
- 2005-05-03 EP EP15180557.9A patent/EP2980074A1/fr not_active Ceased
- 2005-05-03 MX MXPA06012612A patent/MXPA06012612A/es active IP Right Grant
- 2005-05-03 SI SI200532001T patent/SI1755596T1/sl unknown
- 2005-05-03 EP EP20130175944 patent/EP2669273A1/fr not_active Withdrawn
- 2005-05-03 WO PCT/US2005/015333 patent/WO2005108349A2/fr not_active Ceased
- 2005-05-03 HU HUE05744537A patent/HUE026242T2/en unknown
- 2005-05-03 PL PL05744537T patent/PL1755596T3/pl unknown
- 2005-05-03 EP EP05744537.1A patent/EP1755596B9/fr not_active Expired - Lifetime
2006
- 2006-10-31 IL IL178965A patent/IL178965A/en active IP Right Grant
- 2006-11-27 NO NO20065441A patent/NO341013B1/no unknown
2009
- 2009-01-27 US US12/360,468 patent/US7838678B2/en not_active Expired - Lifetime
2010
- 2010-04-16 AU AU2010201538A patent/AU2010201538B2/en not_active Expired
- 2010-10-08 US US12/900,588 patent/US8513428B2/en active Active
2015
- 2015-11-10 CY CY20151101005T patent/CY1116919T1/el unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
WO2005108349A3 (fr)	2006-11-02
AU2010201538B2 (en)	2012-09-06
EP2669273A1 (fr)	2013-12-04
EP1755596B1 (fr)	2015-08-12
IL178965A (en)	2011-05-31
RS54284B1 (sr)	2016-02-29
HRP20150962T1 (xx)	2015-10-09
BRPI0509595A (pt)	2007-10-16
NO20065441L (no)	2006-11-27
EP1755596A2 (fr)	2007-02-28
HUE026242T2 (en)	2016-06-28
US20110124689A1 (en)	2011-05-26
NO341013B1 (no)	2017-08-07
US20050256202A1 (en)	2005-11-17
CA2565629A1 (fr)	2005-11-17
AU2005240622B2 (en)	2010-02-11
JP2007536245A (ja)	2007-12-13
SI1755596T1 (sl)	2015-10-30
US7829720B2 (en)	2010-11-09
US8513428B2 (en)	2013-08-20
AU2010201538A1 (en)	2010-05-13
BRPI0509595B1 (pt)	2019-05-14
CY1116919T1 (el)	2017-04-05
EP2980074A1 (fr)	2016-02-03
KR101153606B1 (ko)	2012-06-11
AU2005240622A1 (en)	2005-11-17
HRP20150962T2 (hr)	2016-04-08
IL178965A0 (en)	2007-03-08
JP5086069B2 (ja)	2012-11-28
DK1755596T5 (en)	2016-05-23
WO2005108349A2 (fr)	2005-11-17
BRPI0509595B8 (pt)	2021-05-25
CA2565629C (fr)	2012-07-31
US7838678B2 (en)	2010-11-23
PL1755596T3 (pl)	2016-04-29
KR20070006935A (ko)	2007-01-11
DK1755596T3 (en)	2015-11-16
PT1755596E (pt)	2015-11-19
ES2552219T3 (es)	2015-11-26
MXPA06012612A (es)	2006-12-15
US20090203630A1 (en)	2009-08-13
EP1755596B9 (fr)	2016-02-10
CA2777216A1 (fr)	2005-11-17

Publication	Publication Date	Title
EP1755596A4 (fr)	2010-12-29	Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes
EP1734986A4 (fr)	2009-07-22	Procede pour la modulation de l'appetit
FR2873685B1 (fr)	2007-06-22	Procede d'obtention de ceramiques poreuses
FR2842200B1 (fr)	2005-12-16	Procede pour l'obtention de polysaccharides modifies
FR2856982B1 (fr)	2006-04-28	Capsules de bouchage ameliorees et procede pour les fabriquer
FR2837385B1 (fr)	2004-05-28	Procede d'obtention de phytoalexines
DE60235767D1 (de)	2010-05-06	Sublimationsmuster-giessverfahren
EP1718962A4 (fr)	2008-06-25	Systeme et procede pour le reperage et la quantification d'entites chimiques
EP1899198A4 (fr)	2010-02-17	Mecanisme de retenue liberable et procede d'utilisation
FR2868414B1 (fr)	2006-11-10	Procede de production d'alpha-alumine particulaire et apha-alumine particulaire produite par ce procede
FR2840307B1 (fr)	2006-07-07	Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
MA26407A1 (fr)	2004-12-01	Procede de preparation de combretastatines
FR2818979B1 (fr)	2003-05-30	Procede de preparation d'imidaclopride
EP1740923A4 (fr)	2011-01-05	Procede de compensation d'hysterese
FR2833272B1 (fr)	2004-02-27	Nouvelles phytases et procede de production de ces phytases
FR2891163B1 (fr)	2009-12-18	Catalyseur pour la preparation du pentafluoroethane et le procede de preparation de celui-ci
EP1498501A4 (fr)	2006-02-15	Procede de production d'acier martensitique inoxydable
EP1565448A4 (fr)	2008-04-23	Procede de preparation de 10h-dibenzo b,f 1,4 thiazepin-11-one
FR2846977B1 (fr)	2007-04-06	Procede pour ameliorer la qualite de non tisses
EP1740531A4 (fr)	2012-02-29	Derives d'indene et procede de preparation correspondant
EP1637883A4 (fr)	2006-07-19	Procede d'imunochromatographie
FR2869030B1 (fr)	2006-11-10	Procede de production d'alpha-alumine particulaire
EP1745000A4 (fr)	2010-05-26	Nouvelles anthraquinones et leur procede de preparation et d'utilisation
FR2804427B1 (fr)	2002-09-06	Procede de preparation de cetones alpha-halogenees
FR2827285B1 (fr)	2003-12-05	Reactif et procede pour la perfluoroalcoylation

Legal Events

Date	Code	Title	Description
2007-01-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2007-02-28	17P	Request for examination filed	Effective date: 20061106
2007-02-28	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2007-02-28	AX	Request for extension of the european patent	Extension state: AL BA HR LV MK YU
2007-05-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1096038 Country of ref document: HK
2007-06-06	RIN1	Information on inventor provided before grant (corrected)	Inventor name: SRIVASTAVA, SUSHIL, K. Inventor name: DAVIDOVICH, MARTHA Inventor name: GOUGOUTAS, JACK, Z. Inventor name: MALLEY, MARY, F. Inventor name: LOTZ, BRUCE, T. Inventor name: KIM, SOOJIN
2007-08-08	RAX	Requested extension states of the european patent have changed	Extension state: YU Payment date: 20061106 Extension state: MK Payment date: 20061106 Extension state: LV Payment date: 20061106 Extension state: HR Payment date: 20061106
2010-12-29	A4	Supplementary search report drawn up and despatched	Effective date: 20101126
2010-12-29	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/44 20060101ALI20101122BHEP Ipc: C07D 213/56 20060101AFI20101122BHEP
2011-08-10	17Q	First examination report despatched	Effective date: 20110706
2014-03-05	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
2015-02-24	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-03-25	INTG	Intention to grant announced	Effective date: 20150224
2015-07-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2015-07-10	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2015-08-12	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2015-08-12	AX	Request for extension of the european patent	Extension state: HR LV MK YU
2015-08-12	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2015-08-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2015-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 742013 Country of ref document: AT Kind code of ref document: T Effective date: 20150815
2015-08-19	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
2015-09-09	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2015-09-11	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20150962 Country of ref document: HR
2015-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: MARKS AND CLERK (LUXEMBOURG) LLP, CH
2015-09-17	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602005047216 Country of ref document: DE
2015-10-09	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20150962 Country of ref document: HR
2015-11-07	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2015-11-16	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20151112
2015-11-19	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20151104
2015-11-26	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2552219 Country of ref document: ES Kind code of ref document: T3 Effective date: 20151126
2015-12-01	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2016-01-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E011272 Country of ref document: EE Effective date: 20151103
2016-01-20	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2016-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151113
2016-04-08	REG	Reference to a national code	Ref country code: HR Ref legal event code: T2IS Ref document number: P20150962 Country of ref document: HR
2016-04-12	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12
2016-05-13	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602005047216 Country of ref document: DE
2016-05-23	REG	Reference to a national code	Ref country code: DK Ref legal event code: T5 Effective date: 20160520
2016-06-01	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 20127 Country of ref document: SK
2016-06-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2016-06-17	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20150402288 Country of ref document: GR Effective date: 20160201
2016-06-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2016-06-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E026242 Country of ref document: HU
2016-07-01	REG	Reference to a national code	Ref country code: SK Ref legal event code: T4 Ref document number: E 20127 Country of ref document: SK
2016-07-20	26N	No opposition filed	Effective date: 20160513
2017-04-13	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13
2018-04-11	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14
2018-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 742013 Country of ref document: AT Kind code of ref document: T Effective date: 20150812
2019-01-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: HC1A Ref document number: E011272 Country of ref document: EE
2019-02-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 602005047216 Country of ref document: DE Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU Ref country code: DE Ref legal event code: R081 Ref document number: 602005047216 Country of ref document: DE Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITE, CH Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, STEINHAUSEN, CH
2019-02-22	REG	Reference to a national code	Ref country code: LU Ref legal event code: HC Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND Effective date: 20190123
2019-03-28	REG	Reference to a national code	Ref country code: HR Ref legal event code: PNAN Ref document number: P20150962 Country of ref document: HR Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Ref country code: HU Ref legal event code: HC9C Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITE, CH Free format text: FORMER OWNER(S): BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
2019-03-29	REG	Reference to a national code	Ref country code: SI Ref legal event code: SP73 Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITE; CH Effective date: 20190222
2019-05-03	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20190410 Year of fee payment: 15
2019-05-06	REG	Reference to a national code	Ref country code: SK Ref legal event code: TC4A Ref document number: E 20127 Country of ref document: SK Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITE, CH Effective date: 20190409
2019-05-08	REG	Reference to a national code	Ref country code: BE Ref legal event code: HC Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE; FORMER OWNER NAME: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND Effective date: 20190219 Ref country code: BE Ref legal event code: FP Effective date: 20151105
2019-05-23	REG	Reference to a national code	Ref country code: ES Ref legal event code: PC2A Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Effective date: 20190523
2020-05-15	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20200421 Year of fee payment: 16
2020-12-18	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1096038 Country of ref document: HK
2021-03-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PFA Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITE, CH Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
2021-05-14	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20210428 Year of fee payment: 17
2022-05-27	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20220428 Year of fee payment: 18
2023-04-11	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19
2023-05-12	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20230412 Year of fee payment: 19
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230514
2024-05-10	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20150962 Country of ref document: HR Payment date: 20240408 Year of fee payment: 20
2024-05-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20240426 Year of fee payment: 20
2024-05-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20240415 Year of fee payment: 20
2024-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240328 Year of fee payment: 20
2024-07-01	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IS Payment date: 20240405 Year of fee payment: 20
2024-07-05	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20240410 Year of fee payment: 20
2024-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240402 Year of fee payment: 20
2024-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LT Payment date: 20240405 Year of fee payment: 20
2024-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240328 Year of fee payment: 20
2024-07-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20240426 Year of fee payment: 20 Ref country code: DK Payment date: 20240515 Year of fee payment: 20
2024-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20240412 Year of fee payment: 20
2024-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20240602 Year of fee payment: 20
2024-07-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240611 Year of fee payment: 20
2024-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20240425 Year of fee payment: 20 Ref country code: CZ Payment date: 20240417 Year of fee payment: 20
2024-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20240412 Year of fee payment: 20
2024-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RO Payment date: 20240412 Year of fee payment: 20 Ref country code: IT Payment date: 20240411 Year of fee payment: 20 Ref country code: FI Payment date: 20240514 Year of fee payment: 20 Ref country code: EE Payment date: 20240403 Year of fee payment: 20 Ref country code: CY Payment date: 20240405 Year of fee payment: 20 Ref country code: BG Payment date: 20240417 Year of fee payment: 20 Ref country code: SI Payment date: 20240415 Year of fee payment: 20
2024-08-01	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20240405 Year of fee payment: 20 Ref country code: PT Payment date: 20240503 Year of fee payment: 20
2024-08-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20240419 Year of fee payment: 20 Ref country code: SE Payment date: 20240328 Year of fee payment: 20 Ref country code: HU Payment date: 20240415 Year of fee payment: 20 Ref country code: BE Payment date: 20240422 Year of fee payment: 20
2025-05-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 602005047216 Country of ref document: DE
2025-05-07	REG	Reference to a national code	Ref country code: NL Ref legal event code: MK Effective date: 20250502
2025-05-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-05-26	REG	Reference to a national code	Ref country code: LT Ref legal event code: MM9A Effective date: 20250503
2025-05-28	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20250502 Ref country code: SK Ref legal event code: MK4A Ref document number: E 20127 Country of ref document: SK Expiry date: 20250503
2025-05-29	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20250529
2025-06-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK07 Ref document number: 742013 Country of ref document: AT Kind code of ref document: T Effective date: 20250503
2025-06-30	REG	Reference to a national code	Ref country code: HR Ref legal event code: PB20 Ref document number: P20150962 Country of ref document: HR Effective date: 20250503
2025-07-01	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2025-07-02	REG	Reference to a national code	Ref country code: IE Ref legal event code: MK9A
2025-07-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250504 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250502
2025-07-10	REG	Reference to a national code	Ref country code: BE Ref legal event code: MK Effective date: 20250503
2025-07-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250514
2025-07-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250503
2025-07-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250503
2025-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20250503